[COVID-19 pandemia: Impact on the cariovascular system. Data of 1st April 2020]

Ann Cardiol Angeiol (Paris). 2020 May;69(3):107-114. doi: 10.1016/j.ancard.2020.04.001. Epub 2020 Apr 7.
[Article in French]

Abstract
in English, French

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells with angiotensin receptors, leading to pneumonia linked to COVID-19. The virus has a double impact on the cardiovascular system, the infection will be more intense if the host has cardiovascular co-morbidities and the virus can cause life-threatening cardiovascular lesions. Therapies associated with COVID-19 may have adverse cardiovascular effects. Therefore, special attention should be given to cardiovascular protection during COVID-19 infection.

Le syndrome respiratoire aigu sévère coronavirus 2 (SARS-CoV-2) infecte les cellules hôtes par les récepteurs de l’angiotensine, conduisant à une pneumonie liée au COVID-19. À un niveau cardiaque, le virus a un double impact ; en effet, l’infection sera plus grave si l’hôte possède des comorbidités cardiovasculaires, et le virus peut causer des lésions cardiovasculaires pouvant engager le pronostic vital. Les thérapeutiques associées au COVID-19 peuvent avoir des effets indésirables cardiovasculaires. Une attention particulière doit être accordée à la protection cardiovasculaire pendant l’infection au COVID-19.

Keywords: COVID-19; Cardiac impact; Gestion des thérapeutiques; Impact cardiaque; Therapeutics management.

Publication types

  • Review

MeSH terms

  • Antimalarials / adverse effects
  • Antimalarials / therapeutic use
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use
  • Azithromycin / adverse effects
  • Azithromycin / therapeutic use
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity*
  • COVID-19
  • Cardiomyopathies / virology
  • Cardiovascular Diseases / complications*
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Cerebrovascular Disorders / complications
  • Cerebrovascular Disorders / prevention & control
  • Cerebrovascular Disorders / virology
  • Chloroquine / adverse effects
  • Chloroquine / therapeutic use
  • Comorbidity
  • Coronary Disease / complications
  • Coronary Disease / prevention & control
  • Coronary Disease / virology
  • Coronavirus Infections / complications*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / prevention & control
  • Drug Interactions
  • Drug Therapy, Combination / adverse effects
  • Female
  • Humans
  • Hydroxychloroquine / adverse effects
  • Hydroxychloroquine / therapeutic use
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Male
  • Methylprednisolone / adverse effects
  • Pandemics / prevention & control
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / prevention & control
  • Risk Factors
  • SARS-CoV-2
  • Virus Internalization / drug effects

Substances

  • Antimalarials
  • Antiviral Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hydroxychloroquine
  • Azithromycin
  • Chloroquine
  • Methylprednisolone